KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Net Margin (2018 - 2025)

Historic Net Margin for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to 2.31%.

  • Amneal Pharmaceuticals' Net Margin rose 6400.0% to 2.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.96%, marking a year-over-year increase of 76200.0%. This contributed to the annual value of 4.18% for FY2024, which is 6700.0% down from last year.
  • Amneal Pharmaceuticals' Net Margin amounted to 2.31% in Q3 2025, which was up 6400.0% from 4.92% recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Net Margin peaked at 4.92% during Q2 2025, and registered a low of 21.6% during Q2 2022.
  • Its 5-year average for Net Margin is 1.85%, with a median of 0.43% in 2022.
  • In the last 5 years, Amneal Pharmaceuticals' Net Margin tumbled by -243100bps in 2022 and then surged by 235900bps in 2023.
  • Amneal Pharmaceuticals' Net Margin (Quarter) stood at 1.19% in 2021, then soared by 40bps to 0.71% in 2022, then plummeted by -2150bps to 15.99% in 2023, then surged by 82bps to 2.84% in 2024, then soared by 181bps to 2.31% in 2025.
  • Its Net Margin stands at 2.31% for Q3 2025, versus 4.92% for Q2 2025 and 3.54% for Q1 2025.